Category: Market/Novel Tech

Month: 17 Oct 2014

Issue: not yet available

pSivida Corporation receives $25M milestone payment from licensee Alimera Sciences Inc. following FDA approval of Iluvien

pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a company based in Massachusetts, USA, has announced the receipt of approval from the FDA for its sustained release fluocinolone acetonide intravitreal implant (Iluvien) for the treatment of diabetic macular edema (DME). Achievement of the regulatory milestone entitles pSivida to a $25 million payment from its licensee, Alimera Sciences Inc., in addition to a 20% share of the future net profits from sales of the drug in the U.S., schedule to being in Q1 2015. The treatment will be indicated for patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP). According to the company, a single injection of the Iluvien micro-insert provides sustained treatment of DME for 36 months. pSivida’s licensee and lead commercial sponsor, Alimera Sciences, Inc., stated that Iluvien was approved without any restriction requiring patients to have undergone, or be scheduled for, cataract surgery.

Back to previous

Related News

Gearoid Tuohy

editor

by Dr. Gearóid Tuohy   Dear EURETINA Members,   A very warm welcome to the December 4th, 2017 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is […]